The IPF therapeutic market is currently dominated by the
only two drugs that have gained marketing approval for IPF - Roche’s Esbriet
and Boehringer Ingelheim’s Ofev. Esbriet was the first drug to gain approval
for IPF in 2011 when it was approved for use in Europe, a full four years
before rival Ofev. However, both gained approval into the largest IPF market of
the US on the same day in October 2014.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/643852-opportunityanalyzer-idiopathic-pulmonary-fibrosis-forecast-to-2025
The top-selling drug in IPF in value terms is Roche’s
Esbriet, which GlobalData estimates generated approximately $572m in 2015 from
the seven major markets. There is high R&D activity for the development of
new therapies for IPF and eight promising therapies can potentially enter the
market from 2015 to 2025. Numerous novel targets are being studied in the IPF
pipeline, with major pharmaceutical players Roche, Sanofi, Bristol-Myers
Squibb, and Biogen all active in the development process. Other promising pipeline
candidates include FibroGen’s CTGF inhibitor, Promedior’s PTX2 protein,
Afferent’s P2X3 receptor antagonist, and MediciNova’s 5-LO/LT pathway
inhibitor. The continued uptake of Esbriet and Ofev, combined with the
introduction of new novel drugs will shape the future competitive landscape and
drive growth in the IPF market. Highlights Key Questions Answered - What was
the impact of Esbriet and Ofev on the IPF market following their FDA approval
in 2014 and what is their future outlook within this market? - What do
physicians think about Esbriet and Ofev, and how they will be used for IPF
during the forecast period? - What is the significance of late-phase pipeline
products and how will their launch shape the future treatment landscape in IPF?
- What are the unmet needs within the IPF market? - What are the remaining
opportunities within the IPF market? Key Findings - The main drivers of growth
for the IPF market include the increasing uptake of Esbriet and Ofev, the
launch of new novel treatment options during the second half of the forecast
period, and the increasing number of prevalent cases of IPF. - R&D
strategies include the development of novel therapies, partnerships and
acquisitions, combination of therapies, and targeting niche patient subpopulations.
- The IPF therapeutic market is characterized by significant unmet needs. The
most pressing unmet need is the development of a product capable of either
stabilizing or reversing progression of IPF. Current therapies Esbriet and Ofev
do not address this need and are only capable of slowing disease progression. -
With high R&D activity in the IPF therapeutic market, physicians are
looking forward to pipeline products becoming available, which will enable them
to improve patients’ treatment. Scope - Overview of IPF, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current
treatment options. - Annualized IPF therapeutic market revenue, annual cost of
therapy and treatment usage pattern data from 2015 and forecast for ten years
to 2025. - Key topics covered include strategic competitor assessment, market
characterization, unmet needs, and implications for the IPF therapeutics
markets. - Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of mid-stage
pipeline drugs. - Analysis of the current and future market competition in the
global IPF therapeutics markets. Insightful review of the key industry drivers,
restraints and challenges. Each trend is independently researched to provide
qualitative analysis of its implications. Reasons to buy The report will enable
you to - - Develop and design in-licensing and out-licensing strategies through
a review of pipeline products and technologies, and by identifying the
companies with the most robust pipeline. - Develop business strategies by
understanding the trends shaping and driving the global IPF therapeutic
markets. - Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the global
IPF therapeutic markets in the future. - Formulate effective sales and
marketing strategies by understanding the competitive landscape and by
analyzing the performance of various competitors. - Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage. - Track drug sales in the
global IPF therapeutic markets from 2015-2025. - Organize sales and marketing
efforts by identifying the market categories and segments that present maximum
opportunities for consolidations, investments and strategic partnerships.
Table of
Contents
1 Table of Contents 10 1.1 List of Tables 15 1.2 List of
Figures 18 2 Introduction 19 2.1 Catalyst 19 2.2 Related Reports 20 3 Disease
Overview 21 3.1 Etiology and Pathophysiology 24 3.1.1 Etiology 24 3.1.2
Pathophysiology 25 3.2 Classification or Staging System 28 3.3 Prognosis 31 3.4
Quality of Life 31 3.5 Symptoms 32 4 Epidemiology 34 4.1 Disease Background 34
4.2 Risk Factors and Comorbidities 34 4.3 Global Trends 36 4.3.1 Incidence 36
4.3.2 Prevalence 37 4.4 Forecast Methodology 39 4.4.1 Sources Used 39 4.4.2
Forecast Assumptions and Methods 44 4.4.3 Sources Not Used 51 4.5
Epidemiological Forecast for IPF (2015-2025) 52 4.5.1 Diagnosed Incident Cases
52 4.5.2 Diagnosed Prevalent Cases 60 4.5.3 IPF Mortality 67 4.6 Discussion 72
4.6.1 Epidemiological Forecast Insight 72 4.6.2 Limitations of the Analysis 73
4.6.3 Strengths of the Analysis 74 5 Current Treatment Options 75 5.1 Overview
75 5.2 Product Profiles - Major Brands 77 5.2.1 Esbriet (Pirfenidone) 77 5.2.2
Ofev (Nintedanib) 82 5.2.3 Fluimucil (N-acetylcysteine) 87 6 Unmet Needs
Assessment and Opportunity Analysis 91 6.1 Overview 91 6.2 Lack of an
Efficacious Drug 92 6.2.1 Overview 92 6.2.2 Gap Analysis 93 6.2.3 Opportunity
93 6.3 Patient Access to Costly Treatments 93 6.3.1 Overview 93 6.3.2 Gap
Analysis 94 6.3.3 Opportunity 95 6.4 Early and Prompt Diagnosis 95 6.4.1
Overview 95 6.4.2 Gap Analysis 96 6.4.3 Opportunity 97 6.5 Unrecognized Disease
97 6.5.1
Access Report @ https://www.wiseguyreports.com/reports/643852-opportunityanalyzer-idiopathic-pulmonary-fibrosis-forecast-to-2025
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
No comments:
Post a Comment